Probiotics in Gastrointestinal Diseases

Francisco Guarner

doi:10.1128/9781555815462.ch20

Chapter 20 : Probiotics in Gastrointestinal Diseases

VIEW AFFILIATIONS HIDE AFFILIATIONS

Affiliations: 1: Digestive System Research Unit, University Hospital Vall d’Hebron, CIBEREHD, Passeig Vall d’Hebron, 119–129, 08035 Barcelona, Spain

Content Type: Monograph

Publication Year: 2008

Category: Clinical Microbiology

Book DOI: 10.1128/9781555815462

Chapter DOI: 10.1128/9781555815462.ch20

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:

Probiotics in Gastrointestinal Diseases, Page 1 of 2

< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555815462/9781555814038_Chap20-1.gif /docserver/preview/fulltext/10.1128/9781555815462/9781555814038_Chap20-2.gif

Abstract:

A large and diverse community of commensal bacteria is harbored in the human gut, in a symbiotic arrangement that influences both the physiology and pathology of the host. Microbial ecology in the gut can be modulated by pharmacological and nutritional interventions with probiotics and prebiotics, and a balanced microbial environment would likely promote symbiotic functions of bacteria and enhance human health. In controlled human studies, probiotics and prebiotics have been used for improving certain metabolic functions of the microbiota, for protection against infections, and for modulation of the immune system. This chapter summarizes the recommendation grades for the use of probiotics in gastroenterology according to the criteria of evidence-based medicine. Current clinical research is focused mainly at establishing the role and efficacy of probiotics and prebiotics in the prevention and control of inflammatory bowel disease (IBD) and colon cancer. Experimental studies have yielded convincing evidence of their potential utility for these indications. However, human studies have failed in some attempts to provide effective therapeutic strategies with probiotics and prebiotics. It is likely that the development of improved tools to investigate gut colonization will provide a more complete picture of the actual scenario in inflammatory disorders and colon cancer. As a consequence, new interventions will aim towards more robust modifications or remodeling of intestinal microbial populations with applications for improving gut health.

Citation: Guarner F. 2008. Probiotics in Gastrointestinal Diseases, p 255-269. In Versalovic J, Wilson M (ed), Therapeutic Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555815462.ch20

Key Concept Ranking

Microbial Ecology: 0.65621436
Traveler's Diarrhea: 0.5673828
Small Intestine: 0.45815694
Gastrointestinal Diseases: 0.45647302
Large Intestine: 0.45099822
Lactic Acid Bacteria: 0.44696316
Nosocomial Diarrhea: 0.4244792

0.65621436

Highlighted Text: Show | Hide

Full text loading...

Figures

Probiotics in Gastrointestinal Diseases

[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815462.ch20-1,webId=/content/author/10.1128/9781555815462.ch20-1,properties={foaf_givenname=Francisco, foaf_name=Francisco Guarner, foaf_surname=Guarner, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555815462.ch20-aff1]]}]]

/content/10.1128/9781555815462.ch20.ch20fig01

Figure 1

The specialized lymphoid follicles of the gut mucosa are major sites for induction and regulation of immune responses. Multiple and diverse interactions between microbes, epithelium, and gut lymphoid tissues are constantly reshaping local and systemic mechanisms of immunity. Gut microbes stimulate clonal expansion of lymphocytes in follicles, and the mechanisms which determine the phenotype differentiation of T-helper cells are not fully understood. However, experimental evidence indicates that innate recognition of bacteria by epithelial cells and/or antigen-presenting cells may play critical roles in the induction of either effector or regulatory pathways. Costimulatory signals (cytokines) released by these cell types dictate polarization of the adaptive immune response.

10.1128/9781555815462/ch20fig1_thmb.gif

10.1128/9781555815462/ch20fig1.gif

Figure 1

/content/10.1128/9781555815462.ch20.ch20fig02

Figure 2

Relative risks (and 95% confidence intervals) of diarrhea in subjects on antibiotics and probiotics as normalized by the incidence of diarrhea in control subjects on antibiotics and placebo in 14 controlled clinical trials. Twelve studies estimated a relative risk lower than 1, and in seven of these studies the upper limit of the 95% confidence interval was also below 1. Overall, the combined relative risk is significantly reduced, as determined in published meta-analyses ( Cremonini et al., 2002 ; D’Souza et al., 2002 ; Szajewska and Mrukowicz, 2005 ; Sazawal et al., 2006 ). LGG, L. rhamnosus GG.

10.1128/9781555815462/ch20fig2_thmb.gif

10.1128/9781555815462/ch20fig2.gif

Figure 2

/content/10.1128/9781555815462.ch20.ch20fig03

Figure 3

Colorectal cancer is induced by a series of mutational events in a number of critical genes of epithelial stem cells in the mucosa. The presence in the colonic lumen of DNA-damaging agents could represent an important risk factor for colonic cancer. Diet and gut bacteria are likely to play a role in the production and/or elimination of genotoxic compounds in the colonic lumen. The SYNCAN study found a decrease in genotoxicity indexes in colonic mucosal biopsy samples from patients taking a synbiotic (prebiotic plus two probiotic strains), whereas this change was not observed in subjects taking a placebo (data from Rafter et al., 2007 ). This finding suggests a decreased mucosal exposure to genotoxins associated with the consumption of the synbiotic.

10.1128/9781555815462/ch20fig3_thmb.gif

10.1128/9781555815462/ch20fig3.gif

Figure 3

References

/content/book/10.1128/9781555815462.ch20

1. Alberda, C.,, L. Gramlich,, J. Meddings,, C. Field,, L. McCargar,, D. Kutsogiannis,, R. Fedorak,, and K. Madsen. 2007. Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial. Am. J. Clin. Nutr. 85: 816– 823.

2. Allen, S. J.,, B. Okoko,, E. Martinez,, G. Gregorio, and, L. F. Dans. 2004. Probiotics for treating infectious diarrhoea. Cochrane Database Syst. Rev. 2:CD003048.

3. Anderson, A. D.,, C. E. McNaught,, P. K. Jain,, and J. MacFie. 2004. Randomised clinical trial of synbiotic therapy in elective surgical patients. Gut 53: 241– 245.

4. Bausserman, M., and, S. Michail. 2005. The use of Lactobacillus GG in irritable bowel syndrome in children :a double-blind randomized control trial. J. Pediatr. 147: 197– 201.

5. Borruel, N.,, M. Carol,, F. Casellas,, M. Antolín, F. de Lara,, E. Espín,, J. Naval,, F. Guarner, and, J. R. Malagelada. 2002. Increased mucosal TNFαproduction in Crohn’s disease can be downregulated ex vivo by probiotic bacteria. Gut 51: 659– 664.

6. Bousvaros, A.,, S. Guandalini,, R. N. Baldassano,, C. Botelho,, J. Evans,, G. D. Ferry,, B. Goldin,, L. Hartigan,, S. Kugathasan,, J. Levy,, K. F. Murray,, M. Oliva-Hemker,, J. R. Rosh,, V. Tolia,, A. Zholudev,, J. A.Vanderhoof, and, P. L. Hibberd. 2005. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm. Bowel Dis. 11: 833– 839.

7. Casellas, F.,, N. Borruel,, M. Papo,, F. Guarner,, M. Antolín,, S. Videla, and, J. R. Malagelada. 1998. Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm. Bowel Dis. 4: 1– 5.

8. Chermesh, I.,, A. Tamir,, R. Reshef,, S. Chowers,, A. Suissa,, D. Katz,, M. Gelber,, Z. Halpern,, S. Bengmark,, and R. Eliakim. 2007. Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn’s disease. Dig. Dis. Sci. 52: 385– 389.

9. Cremonini, F., S. Di Caro,, E. C. Nista,, F. Bartolozzi,, G. Capelli,, G. Gasbarrini,, and A. Gasbarrini. 2002. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment. Pharmacol. Ther. 16: 1461– 1467.

10. Cummings, J. H.,, J. M. Antoine,, F. Azpiroz,, R. Bourdet-Sicard,, P. Brandtzaeg,, P. C. Calder,, G. R. Gibson,, F. Guarner,, E. Isolauri,, D. Pannemans,, C. Shortt,, S. Tuijtelaars,, and B. Watzl. 2004. PASSCLAIM--gut health and immunity. Eur. J. Nutr. 43(Suppl. 2) : 118– 173.

11. Delia, P.,, G. Sansotta,, V. Donato,, P. Frosina,, G. Messina,, C. De Renzis, and G. Famularo. 2007. Use of probiotics for prevention of radiation-induced diarrhea. World J. Gastroenterol. 13: 912– 915.

12. Deshpande, G.,, S. Rao, and, S. Patole. 2007. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birth weight: a systematic review of randomised controlled trials. Lancet 369: 1614– 1620.

13. de Vrese, M.,, A. Stegelmann,, B. Richter,, S. Fenselau,, C. Laue,, and J. Shrezenmeir. 2001. Probiotics—compensation for lactase insufficiency. Am. J. Clin. Nutr. 73(Suppl) :421S–429S.

14. D’Haens, G. R.,, K. Geboes,, M. Peeters,, F. Baert,, F. Penninckx,, and P. Rutgeerts. 1998. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114: 262– 267.

15. D’Souza, A. L.,, C. Rajkumar,, J. Cooke, and, C. J. Bulpitt. 2002. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. Br. Med. J. 324: 1361– 1366.

16. Eckburg, P. B.,, E. M. Bik,, C. N. Bernstein,, E. Purdom,, L. Dethlefsen,, M. Sargent,, S. R. Gill,, K. E. Nelson, and, D. A. Relman. 2005. Diversity of the human intestinal microbial flora. Science 308: 1635– 1638.

17. Falk, P. G.,, L. V. Hooper,, T. Midtvedt, and, J. I. Gordon. 1998. Creating and maintaining the gastrointestinal ecosystem: what we know and need to know from gnotobiology. Microbiol. Mol. Biol. Rev. 62: 1157– 1170.

18. Furrie, E.,, S. Macfarlane,, A. Kennedy,, J. H. Cummings,, S. V. Walsh, D. A. O’Neil, and, G. T. Macfarlane. 2005. Synbiotic therapy ( Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54: 242– 249.

19. Gawronska, A.,, P. Dziechciarz,, A. Horvath, and, H. Szajewska. 2007. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment. Pharmacol. Ther. 25: 177– 184.

20. Gibson, G. R.,, H. M. Probert,, J. Van Loo,, R. A. Rastall, and, M. B. Roberfroid. 2004. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr. Res. Rev. 17: 259– 275.

21. Gill, H. S., and, F. Guarner. 2004. Probiotics and human health: a clinical perspective. Postgrad. Med. J. 80: 516– 526.

22. Gionchetti, P.,, F. Rizzello,, A. Venturi,, P. Brigidi,, D. Matteuzzi,, G. Bazzocchi,, G. Poggioli,, M. Miglioli,, and M. Campieri. 2000. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 305– 309.

23. Gionchetti, P.,, F. Rizzello,, U. Helwig,, A. Venturi,, K. M. Lammers,, P. Brigidi,, B. Vitali,, G. Poggioli,, M. Miglioli,, and M. Campieri. 2003. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124: 1202– 1209.

24. Guarner, F. 2005. The intestinal flora in inflammatory bowel disease: normal or abnormal? Curr. Opin. Gastroenterol. 21: 414– 418.

25. Guyonnet, D.,, O. Chassany,, P. Ducrotte,, C. Picard,, M. Mouret,, C. H. Mercier,, and C. Matuchansky. 2007. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multi-centre, randomized, double-blind, controlled trial. Aliment. Pharmacol. Ther. 26: 475– 486.

26. Hickson, M.,, A. L. D’Souza,, N. Muthu,, T. R. Rogers,, S. Want,, C. Rajkumar, and, C. J. Bulpitt. 2007. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ. 335:80.

27. Hooper, L. V.,, M. H. Wong,, A. Thelin,, L. Hansson,, P. G. Falk, and, J. I. Gordon. 2001. Molecular analysis of commensal host-microbial relationships in the intestine. Science 291: 881– 884.

28. Hooper, L. V.,, T. Midtvedt, and, J. I. Gordon. 2002. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu. Rev. Nutr. 22: 283– 307.

29. Huang, J. S.,, A. Bousvaros,, J. W. Lee,, A. Diaz, and, E. J. Davidson. 2002. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig. Dis. Sci. 47: 2625– 2634.

30. Ishikawa, H.,, I. Akedo,, Y. Umesaki,, R. Tanaka,, A. Imaoka,, and T. Otani. 2003. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J. Am. Coll. Nutr. 22: 56– 63.

31. Ishikawa, H.,, I. Akedo,, T. Otani,, T. Suzuki,, T. Nakamura,, I. Takeyama,, S. Ishiguro,, E. Miyaoka,, T. Sobue,, and T. Kakizoe. 2005. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int. J. Cancer 116: 762– 767.

32. Johnston, B. C.,, A. L. Supina,, M. Ospina,, and S. Vohra. 2007. Probiotics for the prevention of pediatricantibiotic-associated diarrhea. Cochrane Database Syst. Rev. 2:CD004827.

33. Kajander, K.,, K. Hatakka,, T. Poussa,, M. Farkkila, and, R. Korpela. 2005. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment. Pharmacol. Ther. 22: 387– 394.

34. Kalliomaki, M.,, S. Salminen,, H. Arvilommi,, P. Kero,, P. Koskinen,, and E. Isolauri. 2001. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357: 1076– 1079.

35. Kato, K.,, S. Mizuno,, Y. Umesaki,, Y. Ishii,, M. Sugitani,, A. Imaoka,, M. Otsuka,, O. Hasunuma,, R. Kurihara,, A. Iwasaki,, and Y. Arakawa. 2004. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment. Pharmacol. Ther. 20: 1133– 1141.

36. Kim, H. J.,, M. Camilleri,, S. McKinzie, M. B. Lempke,, D. D. Burton,, G. M. Thomforde, and, A. R. Zinsmeister. 2003. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 17: 895– 904.

37. Kim, H. J.,, M. I. Vazquez Roque,, M. Camilleri,, D. Stephens,, D. D. Burton,, K. Baxter,, G. Thomforde, and, A. R. Zinsmeister. 2005. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 17: 687– 696.

38. Kolars, J. C.,, M. D. Levitt,, M. Aouji, and, D. A. Savaiano. 1984. Yogurt—an autodigesting source of lactose. N. Engl. J. Med. 310: 1– 3.

39. Kruis, W.,, E. Schutz,, P. Fric,, B. Fixa,, G. Judmaier,, and M. Stolte. 1997. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 11: 853– 858.

40. Kruis, W.,, P. Fric,, J. Pokrotnieks,, M. Lukas,, B. Fixa,, M. Kascak,, M. A. Kamm,, J. Weismueller,, C. Beglinger,, M. Stolte,, C. Wolff,, and J. Schulze. 2004. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617– 1623.

41. Kuisma, J.,, S. Mentula,, H. Jarvinen,, A. Kahri,, M. Saxelin,, and M. Farkkila. 2003. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment. Pharmacol. Ther. 17: 509– 515.

42. Lepage, P.,, P. Seksik,, M. Sutren,, M. F. de la Cochetiere,, R. Jian,, P. Marteau,, and J. Dore. 2005. Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. Inflamm. Bowel Dis. 11: 473– 480.

43. Ley, R. E.,, D. A. Peterson, and, J. I. Gordon. 2006. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124: 837– 848.

44. Lichtman, S. M. 2001. Baterial translocation in humans. J. Pediatr. Gastroenterol. Nutr. 33: 1– 10.

45. Lin, H. C. 2004. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 292: 852– 858.

46. Lirussi, F.,, E. Mastropasqua,, S. Orando, and, R. Orlando. 2007. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. 1:CD005165.

47. Liu, Q.,, Z. P. Duan,, D. K. Ha,, S. Bengmark,, J. Kurtovic, and, S. M. Riordan. 2004. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39: 1441– 1449.

48. Macpherson, A.,, U. Y. Khoo,, I. Forgacs,, J. Philpott-Howard, and, I. Bjarnason. 1996. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38: 365– 375.

49. Majamaa, H., and, E. Isolauri. 1997. Probiotics: a novel approach in the management of food allergy. J. Allergy Clin. Immunol. 99: 179– 185.

50. Marteau, P.,, M. Lemann,, P. Seksik,, D. Laharie,, J. F. Colombel,, Y. Bouhnik,, G. Cadiot,, J. C. Soule,, A. Bourreille,, E. Metman,, E. Lerebours,, F. Carbonnel,, J. L. Dupas,, M. Veyrac,, B. Coffin,, J. Moreau,, V. Abitbol,, S. Blum-Sperisen, and, J. Y. Mary. 2006. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55: 842– 847.

51. Mazmanian, S. K., and, D. L. Kasper. 2006. The love-hate relationship between bacterial polysaccharides and the host immune system. Nat. Rev. Immunol. 6: 849– 858.

52. McFarland, L. V. 2007. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med. Infect. Dis. 5: 97– 105.

53. Mimura, T.,, F. Rizzello,, U. Helwig,, G. Poggioli,, S. Schreiber,, I. C. Talbot,, R. J. Nicholls,, P. Gionchetti,, M. Campieri, and, M. A. Kamm. 2004. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53: 108– 114.

54. Niv, E.,, T. Naftali,, R. Hallak, and, N. Vaisman. 2005. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clin. Nutr. 24: 925– 931.

55. Nobaek, S.,, M. L. Johansson,, G. Molin,, S. Ahrne, and, B. Jeppsson. 2000. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am. J. Gastroenterol. 95: 1231– 1238.

56. Olah, A.,, T. Belagyi,, A. Issekutz,, M. E. Gamal, and, S. Bengmark. 2002. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br. J. Surg. 89: 1103– 1107.

57. O’Mahony, L., J. McCarthy,, P. Kelly,, G. Hurley,, F. Luo,, K. Chen,, G. C. O’Sullivan,, B. Kiely,, J. K. Collins,, F. Shanahan, and, E. M. Quigley. 2005. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128: 541– 551.

58. Prantera, C.,, M. L. Scribano,, G. Falasco,, A. Andreoli, and, C. Luzi. 2002. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut 51: 405– 409.

59. Rafter, J.,, M. Govers,, P. Martel,, D. Pannemans,, B. Pool-Zobel,, G. Rechkemmer,, I. Rowland,, S. Tuijtelaars,, and J. van Loo. 2004. PASSCLAIM—diet-related cancer. Eur. J. Nutr. 43(Suppl. 2) : 1147– 1184.

60. Rafter, J.,, M. Bennett,, G. Caderni,, Y. Clune,, R. Hughes,, P. C. Karlsson,, A. Klinder,, M. O’Riordan,, G. C. O’Sullivan,, B. Pool-Zobel,, G. Rechkemmer,, M. Roller,, I. Rowland,, M. Salvadori,, H. Thijs,, J. Van Loo,, B. Watzl, and, J. K. Collins. 2007. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am. J. Clin. Nutr. 85: 488– 496.

61. Rayes, N.,, D. Seehofer,, S. Hansen,, K. Boucsein,, A. R. Muller,, S. Serke,, S. Bengmark,, and P. Neuhaus. 2002. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 74: 123– 127.

62. Rayes, N.,, D. Seehofer,, T. Theruvath,, R. A. Schiller,, J. M. Langrehr,, S. Jonas,, S. Bengmark,, and P. Neuhaus. 2005. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation—a randomized, double-blind trial. Am. J. Transplant. 5: 125– 130.

63. Reid, G.,, M. E. Sanders,, H. R. Gaskins,, G. R. Gibson,, A. Mercenier,, R. Rastall,, M. Roberfroid,, I. Rowland,, C. Cherbut, and, T. R. Klaenhammer. 2003. New scientific paradigms for probiotics and prebiotics. J. Clin. Gastroenterol. 37: 105– 118.

64. Rembacken, B. J.,, A. M. Snelling,, P. M. Hawkey,, D. M. Chalmers, and, A. T. Axon. 1999. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: 635– 639.

65. Rolfe, V. E.,, P. J. Fortun,, C. J. Hawkey,, and F. Bath-Hextall. 2006. Probiotics for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. 4:CD004826.

66. Saavedra, J. M.,, N. A. Bauman,, I. Oung,, J. A. Perman, and, R. H. Yolken. 1994. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 334: 1046– 1049.

67. Sartor, R. B. 2004. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126: 1620– 1633.

68. Savino, F.,, E. Pelle,, E. Palumeri,, R. Oggero, and, R. Miniero. 2007. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 119:e124–e130.

69. Sazawal, S.,, G. Hiremath,, U. Dhingra,, P. Malik,, S. Deb, and, R. E. Black. 2006. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect. Dis. 6: 374– 382.

70. Schultz, M.,, A. Timmer,, H. H. Herfarth,, R. B. Sartor,, J. A. Vanderhoof, and, H. C. Rath. 2004. Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol. 4:5.

71. Suau, A.,, R. Bonnet,, M. Sutren,, J. J. Godon,, G. Gibson,, M. D. Collins,, and J. Dore. 1999. Direct rDNA community analysis reveals a myriad of novel bacterial lineages within the human gut. Appl. Environ. Microbiol. 65: 4799– 4807.

72. Sugawara, G.,, M. Nagino,, H. Nishio,, T. Ebata,, K. Takagi,, T. Asahara,, K. Nomoto,, and Y. Nimura. 2006. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann. Surg. 244: 706– 714.

73. Szajewska, H.,, M. Kotowska,, J. Z. Mrukowicz,, M. Armanska,, and W. Mikolajczyk. 2001. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J. Pediatr. 138: 361– 365.

74. Szajewska, H., and, J. Mrukowicz. 2005. Meta-analysis: nonpathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment. Pharmacol. Ther. 22: 365– 372.

75. Szajewska, H.,, A. Skorka, and, M. Dylag. 2007. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment. Pharmacol. Ther. 25: 257– 264.

76. Tong, J. L.,, Z. H. Ran,, J. Shen,, C. X. Zhang, and, S. D. Xiao. 2007. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment. Pharmacol. Ther. 25: 155– 168.

77. Van Gossum, A.,, O. Dewit,, E. Louis,, G. de Hertogh, F. Baert,, F. Fontaine,, M. DeVos,, M. Enslen,, M. Paintin,, and D. Franchimont. 2007. Multicenter randomized-controlled clinical trial of probiotics ( Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after ileo-caecal resection. Inflamm. Bowel Dis. 13: 135– 142.

78. Van Niel, C. W.,, C. Feudtner,, M. M. Garrison, and, D. A. Christakis. 2002. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 109: 678– 684.

79. Viljanen, M.,, E. Savilahti,, T. Haahtela,, K. Juntunen-Backman,, R. Korpela,, T. Poussa,, T. Tuure,, and M. Kuitunen. 2005. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 60: 494– 500.

80. Walker, R., and, M. Buckley. 2006. Probiotic Microbes: the Scientific Basis. American Academy of Microbiology, American Society for Microbiology, Washington, DC. http://www.asm.org/Academy/index.asp.

81. Watkinson, P. J.,, V. S. Barber,, P. Dark, and, J. D. Young. 2007. The use of pre-, pro- and synbiotics in adult intensive care unit patients: systematic review. Clin. Nutr. 26: 182– 192.

82. Wendakoon, C. N.,, A. B. Thomson, and, L. Ozimeki. 2002. Lack of therapeutic effect of a specially designed yogurt for the eradication of Helicobacter pylori infection. Digestion 65: 16– 20.

83. Whorwell, P. J.,, L. Altringer,, J. Morel,, Y. Bond,, D. Charbonneau,, L. O’Mahony,, B. Kiely,, F. Shanahan, and, E. M. Quigley. 2006. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am. J. Gastroenterol. 101: 1581– 1590.

84. Yamanaka, T.,, L. Helgeland,, I. N. Farstad,, H. Fukushima,, T. Midtvedt,, and P. Brandtzaeg. 2003. Microbial colonization drives lymphocyte accumulation and differentiation in the follicle-associated epithelium of Peyer’s patches. J. Immunol. 170: 816– 822.

85. Zocco, M. A.,, L. Z. dal Verme,, F. Cremonini,, A. C. Piscaglia,, E. C. Nista,, M. Candeli,, M. Novi,, D. Rigante,, I. A. Cazzato,, V. Ojetti,, A. Armuzzi,, G. Gasbarrini,, and A. Gasbarrini. 2006. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 23: 1567– 1574.

86. Zoetendal, E. G.,, A. D. Akkermans,, W. M. Akkermans-van Vliet, J. A. de Visser, and, W. M. de Vos. 2001. The host genotype affects the bacterial community in the human gastrointestinal tract. Microb. Ecol. Health Dis. 13: 129– 134.

87. Zoetendal, E. G.,, A. vom Wright,, T. Vilpponen-Salmela,, K. Ben-Amor,, A. D. L. Akkermans, and, W. M. de Vos. 2002. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl. Environ. Microbiol. 68: 3401– 3407.

Tables

Probiotics in Gastrointestinal Diseases

/content/10.1128/9781555815462.ch20.ch20table01

Table 1

Pathological conditions associated with dysfunction of the gut microbiota

Table 1

Pathological conditions associated with dysfunction of the gut microbiota

/content/10.1128/9781555815462.ch20.ch20table02

Table 2

Clinical studies investigating the efficacy of probiotics in the treatment of IBSa

Table 2

Clinical studies investigating the efficacy of probiotics in the treatment of IBSa

/content/10.1128/9781555815462.ch20.ch20table03

Table 3

Clinical studies investigating the efficacy of probiotics in maintenance of remission in ulcerative colitisa

Table 3

Clinical studies investigating the efficacy of probiotics in maintenance of remission in ulcerative colitisa

/content/10.1128/9781555815462.ch20.ch20table04

Table 4

Clinical studies investigating the efficacy of probiotics in maintenance of remission in Crohn’s disease

Table 4

Clinical studies investigating the efficacy of probiotics in maintenance of remission in Crohn’s disease

/content/10.1128/9781555815462.ch20.ch20table05

Table 5

Probiotics in evidence-based medicine

Table 5

Probiotics in evidence-based medicine